ZNTL

Zentalis Pharmaceuticals, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1725160Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$0.0M

Net Income FY2025

$(137.0M)

EPS (Basic, as reported)

$-1.91

Net Margin FY2025

—

ROE FY2025

-63.4%

Total Equity

$216.0M

Shares Out

72M

Business description

Zentalis Pharmaceuticals, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2019–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 0 → 0

Fiscal yearFY2019⚑FY2020⚑FY2021FY2022FY2023FY2024FY2025

Revenue———00670

Research & development(38)(85)(176)(173)(190)(168)(107)

General & administrative(8)(34)(41)(55)(64)(87)(38)

Total operating expenses(47)(119)(217)(227)(300)(259)(153)

Operating income(47)(119)(217)(227)(300)(191)(153)

Pre-tax income(46)(118)(165)(238)(293)(166)(137)

Income tax expense0000(1)00

Net income(46)(118)(159)(237)(292)(166)(137)

EPS — basic—($4.19)($3.72)($4.48)($4.47)($2.33)($1.91)

EPS — diluted($8.16)($4.19)($3.72)($4.48)($4.47)($2.33)($1.91)

Shares outstanding — basic (M)6284353657172

Shares outstanding — diluted (M)6284353657172

⚑ Weighted-average shares changed ×4.67 between FY2019 and FY2020 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×1.54 between FY2020 and FY2021 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.